BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-80@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Viatris Innovation GmbH — Cenerimod [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Research Study to Evaluate the Ef
 fects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupu
 s Erythematosus.\nSource: https://clinicaltrials.gov/study/NCT05648500\nht
 tps://catalystbrief.girapphe.com/e/80?lang=en\nNot investment advice. Date
 s may change.
URL:https://catalystbrief.girapphe.com/e/80?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
